Spravato Side Effects: What's Normal, What's Monitored
Dissociation, sedation, a blood-pressure check mid-session — Spravato's side effects are real and well documented, not a reason to walk in blind. Here's what actually happens in the room, and what the FDA's black-box warning does and doesn't mean for you.
If you're researching "Spravato side effects" before an evaluation, or before your first session, you deserve the honest picture — not a sanitized one, and not an alarmist one either. Spravato (esketamine) nasal spray is FDA-approved for treatment-resistant depression, and it comes with genuine, well-documented side effects: dissociation, sedation, dizziness, nausea, and a temporary rise in blood pressure during the session itself. It also carries an FDA boxed warning, the agency's strongest safety label. None of that is hidden here.
What it isn't is a reason to rule Spravato out on its own. Every one of these effects is something the in-office monitoring requirement exists specifically to catch and manage, and most patients complete a full treatment course without serious problems. This guide covers what each side effect actually feels like, why two hours of in-office monitoring is federally required, what the black-box warning actually says, and how our team manages all of it with you — not just at your first visit.
What does the "dissociation" everyone mentions actually feel like?
Dissociation is the hallmark Spravato effect, and it's the single most expected thing to happen in the room. Most patients describe a floaty, dreamlike, slightly unreal sensation — some say it feels like watching themselves from a short distance away, or like the edges of the room go soft. It isn't hallucination in the frightening sense some people picture; it's closer to a detached, muffled version of your own senses.
Esketamine produces this effect by blocking NMDA receptors in the brain, the same glutamate pathway thought to be responsible for both its rapid antidepressant action and its dissociative side effects — the two are mechanistically linked, not a separate problem layered on top of the treatment. The sensation typically builds over the first 20–30 minutes, peaks around the 40-minute mark, and fades well before the two-hour monitoring window is over. You're never left to ride it out alone; a member of your care team is in the building the entire time.
The Spravato side effects patients report most
These four account for the large majority of what gets reported in both the clinical trial data and everyday practice. All are actively monitored in the room.
Dissociation & Feeling Detached
A floaty, dreamlike, "watching yourself from outside" sensation during the session. The defining Spravato effect, and the core reason in-office monitoring exists.
Sedation & Drowsiness
Many patients feel noticeably sleepy or sluggish during the observation window. It's tracked at every check-in and typically clears before you're cleared to leave.
Dizziness, Nausea & Vertigo
Common enough that we ask you not to eat for two hours beforehand. An odd taste and mild headache are also frequently reported.
Increased Blood Pressure
Checked before dosing and again around 40 minutes in, when the effect typically peaks — the main clinical reason monitoring is federally required at all.
In the FDA's pivotal trial program, nausea, dissociation, dizziness, vertigo, and headache were each reported by more than one in five patients — common enough to expect, not rare edge cases buried in fine print.
Why does Spravato require two hours of in-office monitoring?
This is the part patients often find most inconvenient about Spravato, and it's worth being honest about that trade-off rather than glossing over it. Every session means blocking out roughly three hours of your day — the dose itself, the two-hour observation period, and arranging a ride home since you can't drive yourself. For someone juggling work and a treatment schedule that starts at twice weekly, that's a real, recurring burden, not a minor inconvenience.
The rationale behind it is just as real. Spravato is only available through a Risk Evaluation and Mitigation Strategy (REMS) — a restricted-distribution program the FDA required specifically because of the drug's boxed warning for sedation, dissociation, and respiratory depression. Your blood pressure is checked before dosing and again near the 40-minute mark, when the effect typically peaks, with monitoring continuing for at least two hours before you're assessed as stable enough to go home. It is genuinely inconvenient, and it is genuinely why serious complications during Spravato treatment are rare: the monitoring is designed to catch the small number of cases where something needs attention before you've left the building.
What does Spravato's black-box warning actually say?
Spravato carries an FDA boxed warning — the agency's strongest labeling requirement, reserved for risks serious enough to demand a patient's and prescriber's direct attention before treatment starts. The warning names five things: sedation, dissociation, respiratory depression, potential for abuse and misuse, and suicidal thoughts and behaviors. That's a genuinely serious list, and it deserves to be read as one rather than minimized.
Context matters, though. A boxed warning is the FDA's way of saying "this requires structured risk mitigation," not necessarily "avoid this drug." The REMS program built around this exact warning is why Spravato can only be administered at certified healthcare settings, always under a provider's direct observation, never as a take-home prescription. On the suicidality item specifically: esketamine is also FDA-approved (in addition to a separately started oral antidepressant) for adults with major depressive disorder experiencing acute suicidal ideation or behavior, based on the ASPIRE I and ASPIRE II trials, which found meaningful reductions in depressive symptoms within 24 hours compared to placebo. The FDA's own labeling is careful to note that Spravato's effectiveness in preventing suicide or reducing suicidal ideation itself hasn't been separately demonstrated — it treats the depressive episode, and patients are monitored for any of these symptoms as standard practice, the same way they're monitored for a blood pressure spike. If you're in crisis right now, call or text 988 (Suicide & Crisis Lifeline) or go to your nearest emergency room.
Is Spravato addictive?
Esketamine is a Schedule III controlled substance under the federal Controlled Substances Act — the same schedule as generic ketamine, since both work on the same NMDA receptor pathway (see our full comparison of Spravato and ketamine for how the two drugs actually relate). The FDA's boxed warning does flag real abuse and misuse potential, and that risk is part of why prescribers are asked to weigh it carefully in patients with a history of substance use disorder.
In everyday practice, the REMS structure meaningfully limits the opportunity for misuse compared to a typical take-home prescription. Spravato is never dispensed directly to you; it's administered on-site, under direct observation, and no dose ever leaves the building in your possession. That doesn't erase the risk the FDA is warning about, but it does mean the misuse pathway that exists for many controlled substances — diversion of a take-home supply — isn't part of how Spravato treatment actually works.
Real side effects, real monitoring, real support in between.
Confidential evaluations, in person or by telemedicine, typically available within 24-48 hours.
How your care team manages side effects with you, not just for you
Side-effect tolerance genuinely varies person to person, and there's no way to predict from the outside exactly how your first session will go. That's a real reason a close, ongoing relationship with your care team matters more here than for a medication you'd just pick up and take on your own. Across the clinical trial program, dissociation and sedation tended to be most pronounced in the first one or two sessions and to lessen as treatment continued — but "tended to" isn't "always," and some patients need a dose or pace adjustment along the way.
That's exactly why treatment isn't a fixed protocol you're run through regardless of how you're doing. Our team reassesses you at every session — not just at intake — and adjusts your schedule based on how you're actually tolerating it, not a generic timeline. Honest reporting matters: telling your care team a side effect felt worse than expected, or that something new came up between sessions, is exactly the information that shapes whether your next dose stays the same, changes, or gets a longer conversation first.
When should a side effect prompt a call to your care team?
Anything happening during the two-hour monitoring window is already being watched in real time — that's the entire point of the observation period, and it's when a provider is best positioned to act immediately if something needs attention. Between sessions, reach out if a symptom persists well past your appointment, gets worse instead of easing, or simply doesn't feel right to you: unusual or prolonged sedation, a headache that won't resolve, a mood or thought change that concerns you, or any blood-pressure-related symptom like a pounding headache or visual changes after you've gone home.
You're not expected to judge on your own whether something is "normal enough" to wait out. A team that's administered treatment at this scale has seen the full range of what's routine and what warrants a same-day conversation, and would rather hear from you and rule something out than have you guess.
What if side effects don't ease up the way they're supposed to?
Most patients see side effects soften over the course of treatment, but "most" isn't "everyone," and it's worth saying plainly that this isn't a program where you're expected to just push through discomfort that isn't improving. If dissociation, sedation, or nausea are still hitting hard several sessions in, that's a legitimate reason to revisit your dose, your pre-session routine (timing of your last meal, hydration, even the music or environment during monitoring), or whether Spravato remains the right fit compared to other options.
This is also where it's worth being honest that Spravato isn't the only treatment in this general category. Some patients considering options like Spravato are also weighing generic ketamine therapy at a separate clinic — a related but genuinely distinct treatment, covered in full in our Spravato vs. ketamine comparison. Side-effect profiles for the two are similar for a specific reason — more on that in that guide.
Keep reading about Spravato
Spravato Treatment at MyPremierMD
The full program: what to expect, our track record across 4 NJ locations, and how to get evaluated.
Learn moreSpravato vs. Ketamine
How esketamine and generic ketamine actually differ — chemically, legally, and in what your insurance will touch.
Learn moreIs Spravato Covered by Insurance?
What treatment-resistant depression criteria insurers look for, and how prior authorization actually works.
Learn moreSpravato side effects: questions patients ask
What are the most common Spravato side effects?
The most frequently reported side effects, seen in more than 1 in 5 patients across the FDA pivotal trials, are nausea, dissociation (feeling detached from yourself or your surroundings), dizziness, vertigo, and headache. A temporary rise in blood pressure, sedation, and an odd taste are also common. Nearly all of these occur during or shortly after the session itself and resolve well before you're cleared to leave.
Is the "detached" or dissociative feeling during Spravato dangerous?
On its own, no — it's the single most expected effect of esketamine and the reason the treatment is monitored in the first place, not a sign something has gone wrong. Most patients describe a floaty, dreamlike, watching-yourself-from-outside sensation that peaks within the first 30–40 minutes and fades well before the two-hour monitoring window ends. Your care team is watching for it directly and will not discharge you until it has cleared.
Why do I have to stay in the office for two hours after a Spravato dose?
Because the FDA requires it. Spravato is only available through a Risk Evaluation and Mitigation Strategy (REMS) — a restricted-distribution program tied to the drug's boxed warning for sedation, dissociation, and respiratory depression. Your blood pressure is checked before dosing and again around the 40-minute mark, when the effect typically peaks, with monitoring continuing for at least two hours total before you're assessed as stable enough to go home.
Can I drive myself home after a Spravato session?
No. The FDA label is specific on this: you should not drive or operate machinery until the next day, after a full night's sleep, even though the acute effects wear off within a couple of hours. You'll need to arrange a ride home from every session — this isn't optional and isn't a MyPremierMD-specific rule, it's a federal requirement tied to the REMS program.
What does Spravato's black-box warning actually say?
The FDA's boxed warning — its strongest labeling requirement — names five risks: sedation, dissociation, respiratory depression, potential for abuse and misuse, and suicidal thoughts and behaviors. It exists precisely because these risks are real, which is exactly why the REMS program requires certified sites, direct provider observation during dosing, and a minimum two-hour monitoring window for every single session, with no take-home doses ever permitted.
Is Spravato addictive?
Esketamine is a Schedule III controlled substance under the same federal classification as ketamine, and the FDA label does warn about abuse and misuse potential — that risk is real and part of why it's monitored. In practice, the REMS structure meaningfully limits the opportunity for misuse compared to a take-home prescription: Spravato is never dispensed to you directly, only administered on-site under direct observation, with no dose ever leaving the building in your possession.
Do Spravato's side effects get better over time?
For most patients, yes. Across the clinical trial program, dissociation and sedation tended to be most pronounced in the first one to two sessions and to lessen as treatment continued, which also matches what our team sees in practice managing thousands of sessions. It isn't universal — some patients need a dose adjustment along the way — which is part of why your care team reassesses you at every visit rather than running a fixed protocol regardless of how you're tolerating it.
When should I call my care team about a Spravato side effect?
Anything happening inside the two-hour monitoring window is already being watched by your care team in real time. Call between sessions if a symptom — unusual sedation, a headache that won't resolve, or any mood or thought change that concerns you — persists well past your appointment, worsens instead of easing, or simply doesn't feel right to you. You're not expected to judge that alone.
Contact MyPremierMD Today
We'll reach out within 24 hours to answer your questions and help you schedule an appointment.